{"id":20737,"date":"2025-01-07T13:16:20","date_gmt":"2025-01-07T05:16:20","guid":{"rendered":"https:\/\/flcube.com\/?p=20737"},"modified":"2025-01-07T13:16:22","modified_gmt":"2025-01-07T05:16:22","slug":"alebund-pharmaceuticals-completes-series-c-financing-to-advance-kidney-disease-pipelines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20737","title":{"rendered":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund&#8217;s kidney disease pipelines and to advance multiple clinical programs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Specific Projects and Market Expansion<\/strong><br>The funding will specifically support the market filing in China for AP301, a best-in-class iron-based phosphate binder, and its global pivotal study. Additionally, it will fund the US\/China Phase II study for AP306, a first-in-class pan phosphate transporter inhibitor. The funds will also be used to further expand the commercial reach of Mircera in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Mircera and Alebund&#8217;s Partnership with Roche<\/strong><br>Mircera (methoxy polyethylene glycol-epoetin beta) is a long-acting erythropoietin (ESA) developed by Swiss giant Roche. It is used to treat anemia related to chronic kidney disease (CKD) and is the first of its kind globally, allowing monthly administration. Mircera was approved in China in April 2018 for the treatment of CKD anemia in patients undergoing treatment with erythropoietic stimulants. In October 2023, Alebund struck a commercialization deal with Roche for exclusive promotion rights to the drug in mainland China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB&#8230;<\/p>\n","protected":false},"author":1,"featured_media":20738,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[627,20],"class_list":["post-20737","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alebund-pharmaceuticals","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund&#039;s kidney disease pipelines and to advance multiple clinical programs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20737\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund&#039;s kidney disease pipelines and to advance multiple clinical programs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20737\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T05:16:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T05:16:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines\",\"datePublished\":\"2025-01-07T05:16:20+00:00\",\"dateModified\":\"2025-01-07T05:16:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0701.png\",\"keywords\":[\"Alebund Pharmaceuticals\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20737#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20737\",\"name\":\"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0701.png\",\"datePublished\":\"2025-01-07T05:16:20+00:00\",\"dateModified\":\"2025-01-07T05:16:22+00:00\",\"description\":\"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund's kidney disease pipelines and to advance multiple clinical programs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20737\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0701.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0701.png\",\"width\":1080,\"height\":720,\"caption\":\"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20737#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund's kidney disease pipelines and to advance multiple clinical programs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20737","og_locale":"en_US","og_type":"article","og_title":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines","og_description":"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund's kidney disease pipelines and to advance multiple clinical programs.","og_url":"https:\/\/flcube.com\/?p=20737","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-07T05:16:20+00:00","article_modified_time":"2025-01-07T05:16:22+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20737#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20737"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines","datePublished":"2025-01-07T05:16:20+00:00","dateModified":"2025-01-07T05:16:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20737"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20737#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","keywords":["Alebund Pharmaceuticals","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20737#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20737","url":"https:\/\/flcube.com\/?p=20737","name":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20737#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20737#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","datePublished":"2025-01-07T05:16:20+00:00","dateModified":"2025-01-07T05:16:22+00:00","description":"Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund's kidney disease pipelines and to advance multiple clinical programs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20737#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20737"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20737#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","width":1080,"height":720,"caption":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20737#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0701.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20737"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20737\/revisions"}],"predecessor-version":[{"id":20739,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20737\/revisions\/20739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20738"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}